Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Next Previous
Trial Profile

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPI-818 (Primary)
  • Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Corvus Pharmaceuticals

    • Most Recent Events

    • 07 Nov 2019 According to a Corvus Pharmaceuticals media release, early clinical data from this study will be presented at the American Society of Hematology (ASH) 61st Annual Meeting 2019 (Orlando, Florida, 7th-10th Dec 2019).
    • 06 Nov 2019 Trial design of Dose-Escalation and Dose-Expansion of CPI-818 in Subjects with Relapsed/Refractory T-Cell Lymphoma released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 16 Jun 2019 Trial design presented at the 24th Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top